HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Jenscare Scientific - Difficult to Achieve Expected Commercialization Results

Pre-IPO Laekna - Low Cost Performance of License-In Mode Leads to A "Rethink" Of Investment Value

Pine Care Group (1989.HK) - Hard to Make Profits Due to Industry Characteristics; Here Is What to Do

Pre-IPO Jenscare Scientific - The Industry Characteristics, the Business and the Challenges

Pre-IPO Shanghai Hanyu Medical Technology - Insights on the Industry and the Products

Peijia Medical (9996.HK) Vs Venus MedTech (2500.HK) Vs CardioFlow (2160.HK)-Pain Points and Solution

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Shanghai NewMed Medical / Equity Capital Markets

<ul>
<li>From <a href="https://www.smartkarma.com/entities/shanghai-newmed-medical-co-ltd" target="_blank" data-smartkarma-citation="entities:34126:1" rel="noopener">Shanghai NewMed Medical (NMM HK)</a>’s pipeline, it can be seen that almost all the candidates do not have obvious advantages in development progress in front of the competing products.</li>
<li>NewMed has little experience in launching and commercializing product candidates, especially as a late-comer. So, the actual commercialization performance could be lower than expected.</li>
<li>Since there are so many uncertainties as well as the poor market sentiment for new IPOs in HKEX, we are conservative about the outlook of NewMed at the current stage.</li>
</ul>


From Shanghai NewMed Medical (NMM HK)’s pipeline, it can be seen that almost all the candidates do not have obvious advantages in development progress in front of the competing products.
NewMed has little experience in launching and commercializing product candidates, especially as a late-comer. So, the actual commercialization performance could be lower than expected.
Since there are so many uncertainties as well as the poor market sentiment for new IPOs in HKEX, we are conservative about the outlook of NewMed at the current stage.


Shanghai Hanyu Medical Technology (SHM HK)

Pre-IPO Shanghai NewMed Medical - Concerns on Fierce Competition and Future Commercialization